Jakafi (ruxolitinib) has a short half-life of about 3 hours, meaning the drug itself clears from your bloodstream relatively quickly. However, its active metabolites linger a bit longer, with a combined half-life of roughly 5.8 hours. Based on standard pharmacokinetic principles, the drug and its metabolites are essentially eliminated within 24 to 30 hours of your last dose. That said, the biological effects of Jakafi can persist well beyond the point when the drug is physically gone.
How Quickly Jakafi Leaves Your Blood
After you take a dose, Jakafi reaches its peak concentration in your blood within 1 to 2 hours. Your body absorbs at least 95% of each oral dose, so very little passes through unabsorbed. From that peak, plasma levels drop fast: the parent drug has a half-life of approximately 3 hours, which means half of it is gone every 3 hours.
Your liver does most of the work breaking Jakafi down, primarily through an enzyme system called CYP3A4, with a smaller contribution from CYP2C9. The resulting metabolites are still pharmacologically active, which is why the effective half-life (parent drug plus metabolites combined) stretches to about 5.8 hours. Using the general rule that a drug is considered cleared after about five half-lives, the total active substance is out of your system in roughly 29 hours after your final dose.
Your body excretes about 74% of a dose through urine and 22% through feces. More than 70% of the drug-related material leaves within the first 24 hours. Less than 1% exits as unchanged ruxolitinib; nearly all of it is broken down into metabolites before being excreted.
Factors That Slow Elimination
Liver function is the most significant variable. In people with hepatic impairment, the elimination half-life increases from about 2.8 hours (in healthy individuals) to between 4.1 and 5.0 hours. That shift means metabolites may take closer to 36 hours to fully clear rather than the typical 24 to 30.
Kidney function, by contrast, does not meaningfully change how fast Jakafi leaves. FDA data show that pharmacokinetics are similar across various degrees of renal impairment compared to people with normal kidney function.
Medications that strongly inhibit the CYP3A4 enzyme (certain antifungals, some antibiotics, and grapefruit juice in large amounts) can slow the breakdown of ruxolitinib, effectively raising its levels in your blood and extending the time it takes to clear. If you’re taking one of these alongside Jakafi, your prescriber will typically adjust the dose to compensate.
Biological Effects Last Longer Than the Drug
Even though the drug itself clears within a day or so, the impact on your body does not switch off that quickly. Jakafi works by blocking specific signaling pathways involved in blood cell production and immune regulation. Once you stop taking it, those pathways reactivate, but the transition is not always smooth.
A well-recognized phenomenon called discontinuation syndrome can occur after stopping Jakafi. Symptoms typically appear within about a week of the last dose, though they can surface anytime in the first 21 days. This happens regardless of what dose you were on, whether you tapered gradually, or whether corticosteroids were used during the transition. Symptoms can include a return or worsening of the original disease symptoms: fever, night sweats, enlarged spleen, and in some cases a serious inflammatory reaction.
This distinction matters. If your question is about drug testing or a medical procedure, the relevant window is roughly 24 to 30 hours. If your concern is about how long your body will feel the effects after discontinuation, the answer is closer to one to three weeks.
Key Numbers at a Glance
- Peak blood level: 1 to 2 hours after a dose
- Half-life of ruxolitinib alone: approximately 3 hours
- Half-life including active metabolites: approximately 5.8 hours
- Full clearance from blood: roughly 24 to 30 hours
- With liver impairment: clearance may take up to about 36 hours
- Discontinuation effects: can appear within 1 to 3 weeks after stopping
Jakafi’s protein binding is high, at about 97%, mostly to albumin. This means a large portion of each dose is bound to proteins in the blood rather than floating freely, but it does not significantly extend the clearance timeline because the drug is metabolized so efficiently by the liver. The volume of distribution is around 72 to 75 liters, indicating that Jakafi spreads moderately throughout body tissues rather than concentrating only in the blood.